Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Tam, Constantine S., Opat, Stephen, Simpson, David, Cull, Gavin, Munoz, Javier, Phillips, Tycel J., Kim, Won Seog, Rule, Simon, Atwal, Siminder Kaur, Wei, Rachel, Novotny, William, Huang, Jane, Wang, Michael, Trotman, Judith
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2021
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270663/
https://ncbi.nlm.nih.gov/pubmed/34152395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020004074
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars